The estimated Net Worth of Ling Zeng is at least $221 Thousand dollars as of 15 December 2021. Ms. Zeng owns over 2,562 units of Dicerna Pharmaceuticals Inc stock worth over $221,064 and over the last 4 years she sold DRNA stock worth over $0. In addition, she makes $0 as Chief Legal Officer and Secretary at Dicerna Pharmaceuticals Inc.
Ling has made over 2 trades of the Dicerna Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she exercised 2,562 units of DRNA stock worth $97,920 on 15 December 2021.
The largest trade she's ever made was exercising 4,556 units of Dicerna Pharmaceuticals Inc stock on 15 September 2021 worth over $174,130. On average, Ling trades about 1,424 units every 18 days since 2020. As of 15 December 2021 she still owns at least 5,784 units of Dicerna Pharmaceuticals Inc stock.
You can see the complete history of Ms. Zeng stock trades at the bottom of the page.
Ling Zeng serves as Chief Legal Officer and Secretary of the Company. Ms. Zeng has gained broad and deep experience in biopharmaceutical law and global drug development, and has held multiple leadership positions in North America, Europe and the Asia-Pacific region. Ms. Zeng joins Dicerna from Novartis AG where she served as deputy head of the legal M&A group responsible for mergers and acquisitions (M&A). In her role, Ms. Zeng was responsible for M&A across all business units and regions. Prior to Novartis, Ms. Zeng held several senior-level positions at Bausch Health Companies, Inc., most recently as vice president and general counsel for Europe, the Middle East and Africa (EMEA), where she was responsible for EMEA legal matters in over 30 countries, and provided counsel on business development efforts, commercial operations, compliance, regulatory and IP strategies, and M&A transactions and integrations. Earlier in her career, Ms. Zeng was an associate at Cleary, Gottlieb, Steen & Hamilton in New York. Ms. Zeng was a research scientist prior to beginning her legal career. Ms. Zeng earned her Juris Doctor degree from Georgetown University where she graduated cum laude . Ms. Zeng holds a Master of Science in biophysics from Brandeis University and a Bachelor of Science in physics from Peking University.
Ling's mailing address filed with the SEC is C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON, MA, 02421.
Over the last 11 years, insiders at Dicerna Pharmaceuticals Inc have traded over $233,644,011 worth of Dicerna Pharmaceuticals Inc stock and bought 2,456,100 units worth $36,501,331 . The most active insiders traders include Capital Management, Llc Kol..., Nicole Vitullo, and Peter Kolchinsky. On average, Dicerna Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of $4,025,674. The most recent stock trade was executed by Douglas W. Pagan on 15 December 2021, trading 2,050 units of DRNA stock currently worth $78,351.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of its flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to its own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and its collaborative partners, they currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna's mission is to interfere - to silence genes, to fight disease, to restore health.
Dicerna Pharmaceuticals Inc executives and other stock owners filed with the SEC include: